A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study
Dominick J. Anaiolillo, Dietmar Trenk(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Nick Curzen(University Hospital Southampton NHS Foundation Trust), Mark B. Effron(Eli Lilly (United States)), Fred Lipkin(Daiichi Sankyo (United States)), Marjorie E. Zettler(Eli Lilly (United States)), Wei Li, Paul A. Gurbel(Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Paul T. Vaitkus(Daiichi Sankyo (United States))
Queensland's institutional digital repository (The University of Queensland)
November 26, 2013
Cited by 0
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
|Circulation|2017|745
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617